International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 295-302 , October 2010

Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future

  • K. Mazumdar

      Affiliations

    • Division of Microbiology, Tulane National Primate Research Center, Covington, LA, USA
    • ,
  • K. Asok Kumar

      Affiliations

    • Department of Pharmacology, College of Pharmacy, 7th of April University, Al-Zawia, Libya
    • ,
  • N.K. Dutta

      Affiliations

    • Division of Bacteriology and Parasitology, Tulane National Primate Research Center, 18703 Three Rivers Road, Covington, LA 70433, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 985 871 6229; fax: +1 985 871 6390.

References 

  1. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother. 2001;48:463–478
  2. Berger-Bächi B. Resistance mechanisms of Gram-positive bacteria. Int J Med Microbiol. 2002;292:27–35
  3. Ray A, Rice LB. Wildcatters welcome: the need for new antimicrobial agents. Therapy. 2004;1:1–5
  4. Walsh C. Where will new antibiotics come from?. Nat Rev Microbiol. 2003;1:65–70
  5. Chan YY, Ong YM, Chua KL. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother. 2007;51:623–630
  6. Kristiansen JE, Hendricks O, Delvin T, Butterworth TS, Aagaard L, Christensen JB, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Chemother. 2007;59:1271–1279
  7. Molnar J. The reversal of drug resistance from bacteria to cancer cells. Curr Drug Targets. 2006;7:789–791
  8. Viveiros M, Jesus A, Brito A, Leandro C, Martins M, Ordway D, et al. Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother. 2005;49:3578–3582
  9. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:719–726
  10. Kristiansen JE. Antimicrobial activity of non-antibiotics. ASM News. 1991;57:135–139
  11. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother. 1997;40:319–327
  12. Amaral L, Lorian V. Effects of chlorpromazine on the cell envelope proteins of Escherichia coli. Antimicrob Agents Chemother. 1991;35:1923–1924
  13. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents. 2001;17:225–228
  14. Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, Molnar J, et al. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents. 2007;30:242–249
  15. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother. 2007;59:1237–1246
  16. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular pathogenic bacteria by phenothiazines and the role of K+ efflux pumps of the bacterium and the killing macrophage. Anti Infect Agents Med Chem. 2008;7:63–72
  17. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnár J, Pagès JM, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents. 2008;31:198–208
  18. Mazumdar K, Dastidar SG, Park JH, Dutta NK. The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur J Clin Microbiol Infect Dis. 2009;28:881–891
  19. Williams JD. The Garrod Lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. J Antimicrob Chemother. 1995;35:721–737
  20. Kumar KA, Ganguly K, Mazumdar K, Dutta NK, Dastidar SG, Chakrabarty AN. Amlodipine: a cardiovascular drug with powerful antimicrobial property. Acta Microbiol Pol. 2003;52:285–292
  21. Sarkar A, Kumar KA, Dutta NK, Chakraborty P, Dastidar SG. Evaluation of in vitro and in vivo antibacterial activity of dobutamine hydrochloride. Indian J Med Microbiol. 2003;21:172–178
  22. Dasgupta A, Jeyaseeli L, Dutta NK, Mazumdar K, Karak P, Dastidar SG, et al. Studies on the antimicrobial potential of the cardiovascular drug lacidipine. In Vivo. 2007;21:847–850
  23. Dutta NK, Mazumdar K, Dastidar SG, Chakrabarty AN, Shirataki Y, Motohashi N. In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-l-DOPA. In Vivo. 2005;19:539–545
  24. Pal T, Dutta NK, Mazumdar K, Dasgupta A, Jeyaseeli L, Dastidar SG. Assessment of antibacterial activity of the cardiovascular drug nifedipine. Oriental Pharm Exp Med. 2006;6:126–133
  25. Mazumdar K, Ganguly K, Kumar KA, Dutta NK, Chakrabarty AN, Dastidar SG. Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride. Microbiol Res. 2003;158:259–264
  26. Dutta NK, Mazumdar K, Baek MW, Kim DJ, Na YR, Park SH, et al. In vitro efficacy of diclofenac against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis. 2008;27:315–319
  27. Dutta NK, Mazumdar K, Seok SH, Park JH. The anti-inflammatory drug diclofenac retains anti-listerial activity in vivo. Lett Appl Microbiol. 2008;47:106–111
  28. Dasgupta A, Mukherjee S, Chaki S, Dastidar SG, Hendricks O, Christensen JB, et al. Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. Int J Antimicrob Agents. 2010;35:174–176
  29. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One. 2010;5:e10069
  30. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!. Int J Antimicrob Agents. 2010;35:524–526
  31. Shepherd WF, Fsadni MG, Raj SA. A clinical evaluation of diclofenac–gentamicin combination eye drops in the control of inflammation after cataract surgery. Diclofenac–Gentamicin versus Gentamicin Study Group. Ocul Immunol Inflamm. 1998;6:13–18
  32. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007;4:e344
  33. Dutta NK, Mazumdar K, DasGupta A, Dastidar SG. Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against Mycobacterium tuberculosis in mice. J Med Microbiol. 2009;58:1667–1668
  34. Gunics G, Motohashi N, Amaral L, Farkas S, Molnár J. Interaction between antibiotics and non-conventional antibiotics on bacteria. Int J Antimicrob Agents. 2000;14:239–242
  35. Molnár J, Haszon I, Bodrogi T, Martonyi E, Turi S. Synergistic effect of promethazine with gentamycin in frequently recurring pyelonephritis. Int Urol Nephrol. 1990;22:405–411
  36. Amaral L, Kristiansen JE, Lorian V. Synergic effect of chlorpromazine on the activity of some antibiotics. J Antimicrob Chemother. 1992;30:556–558
  37. Dutta NK, Mazumdar K, Dastidar SG, Park JH. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int J Antimicrob Agents. 2007;30:336–340
  38. Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother. 2007;59:313–316
  39. Bender AB, Kristiansen JE. Antimicrobial effects of anesthetics and analgesics. Ugeskr Laeger. 1999;161:5814–5817[in Danish]
  40. Wang WH, Wong WM, Dailidiene D, Berg DE, Gu Q, Lai KC, et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 2003;52:490–495
  41. Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dastidar SG, Ray R. Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull. 2004;27:1116–1120
  42. Dasgupta A, Chaki S, Mukherjee S, Lourduraja J, Mazumdar K, Dutta NK, et al. Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine. Eur J Clin Microbiol Infect Dis. 2010;29:239–243
  43. Mazumdar K, Dutta NK, Kumar KA, Dastidar SG. In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biol Pharm Bull. 2005;28:713–717
  44. Rani Basu L, Mazumdar K, Dutta NK, Karak P, Dastidar SG. Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiol Res. 2005;160:95–100
  45. Taylor PL, Wright GD. Novel approaches to discovery of antibacterial agents. Anim Health Res Rev. 2008;9:237–246
  46. Fukumoto A, Kim YP, Hanaki H, Shiomi K, Tomoda H, Omura S. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities. J Antibiot (Tokyo). 2008;61:7–10
  47. Khalil H, Chen T, Riffon R, Wang R, Wang Z. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52:1635–1641
  48. Saha S, Savage PB, Bal M. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant Gram-negative bacterial pathogens. J Appl Microbiol. 2008;105:822–828
  49. Fontán PA, Voskuil MI, Gomez M, Tan D, Pardini M, Manganelli R, et al. The Mycobacterium tuberculosis sigma factor σB is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth. J Bacteriol. 2009;191:5628–5633
  50. Dupre JM, Matyi SA, Singh AK, Song Y, Zaman S, Horan S, et al. The diclofenac stimulon of Staphylococcus aureus. ASM. 2009;A-065/001:94
  51. Janin YL. Antituberculosis drugs: ten years of research. Bioorg Med Chem. 2007;15:2479–2513
  52. Dutta NK, Mazumdar K, Park JH. In vitro synergistic effect of gentamicin with the anti-inflammatory agent diclofenac against Listeria monocytogenes. Lett Appl Microbiol. 2009;48:783–785
  53. Dutta NK, Mazumdar K, DasGupta A, Dastidar SG. In vitro and in vivo efficacies of amlodipine against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis. 2009;7:849–853
  54. Li X, Ruan GR, Lu WL, Hong HY, Liang GW, Zhang YT, et al. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release. 2006;112:186–198
  55. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992;52:2413–2418
  56. Palit P, Ali N. Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis. Antimicrob Agents Chemother. 2008;52:374–377
  57. Suchanova B, Kostiainen R, Ketola RA. Characterization of the in vitro metabolic profile of amlodipine in rat using liquid chromatography–mass spectrometry. Eur J Pharm Sci. 2008;33:91–99
  58. Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol. 2006;46:1212–1216
  59. Bravo G, Kurtansky A, López-Muñoz FJ, Hong E, Rojas G, Villalón CM, et al. Protective action of amlodipine on cardiac negative inotropism induced by lipopolysaccharide in rats. Basic Clin Pharmacol Toxicol. 2007;100:339–344
  60. Chou TC, Yang SP, Pei D. Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-γ-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol. 2002;89:157–163
  61. Barrett JF. Adjunct antimicrobial therapy—prospects for the future. Therapy. 2005;2:67–76

PII: S0924-8579(10)00203-7

doi: 10.1016/j.ijantimicag.2010.05.003

International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 295-302 , October 2010

Article Tools

* Image Usage & Resolution